MX2020004680A - Preparado farmaceutico con excelentes propiedades de estabilidad a la luz y disolucion. - Google Patents

Preparado farmaceutico con excelentes propiedades de estabilidad a la luz y disolucion.

Info

Publication number
MX2020004680A
MX2020004680A MX2020004680A MX2020004680A MX2020004680A MX 2020004680 A MX2020004680 A MX 2020004680A MX 2020004680 A MX2020004680 A MX 2020004680A MX 2020004680 A MX2020004680 A MX 2020004680A MX 2020004680 A MX2020004680 A MX 2020004680A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
drug release
release properties
excellent photostability
polymer
Prior art date
Application number
MX2020004680A
Other languages
English (en)
Inventor
Naomi Hayashi
Masato Gomi
Shohei Aikawa
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2020004680A publication Critical patent/MX2020004680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/802—Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics
    • A61K6/813—Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising iron oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Ceramic Engineering (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Testing Resistance To Weather, Investigating Materials By Mechanical Methods (AREA)

Abstract

Un preparado que se colorea mínimamente a través de irradiación de luz con el recubrimiento de un preparado que contiene un compuesto representado por la Fórmula (I) o una sal de este aceptable desde el punto de vista farmacéutico, o un cristal de este con una sustancia estabilizante a la luz y un polímero, en particular, con uno o más de óxido de titanio y talco usados como la sustancia estabilizante a la luz e hipromelosa usada como el polímero.
MX2020004680A 2017-11-17 2018-11-15 Preparado farmaceutico con excelentes propiedades de estabilidad a la luz y disolucion. MX2020004680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017222068 2017-11-17
PCT/JP2018/042220 WO2019098259A1 (ja) 2017-11-17 2018-11-15 光安定性および溶出性に優れた医薬製剤

Publications (1)

Publication Number Publication Date
MX2020004680A true MX2020004680A (es) 2020-08-13

Family

ID=66540251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004680A MX2020004680A (es) 2017-11-17 2018-11-15 Preparado farmaceutico con excelentes propiedades de estabilidad a la luz y disolucion.

Country Status (13)

Country Link
US (1) US20200375998A1 (es)
EP (1) EP3711767A4 (es)
JP (2) JP6660644B2 (es)
KR (1) KR102562514B1 (es)
CN (1) CN111615390A (es)
AR (1) AR113890A1 (es)
AU (1) AU2018369241B2 (es)
BR (1) BR112020009634B1 (es)
CA (1) CA3082522A1 (es)
IL (1) IL274625B (es)
MX (1) MX2020004680A (es)
TW (1) TWI795462B (es)
WO (1) WO2019098259A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011130A (es) * 2018-04-24 2022-09-09 Shionogi & Co Forma de dosificacion solida que tiene excelente estabilidad.
AR115354A1 (es) * 2018-04-24 2020-12-23 Shionogi & Co Forma de dosis sólida con excelente estabilidad
US20220008429A2 (en) * 2019-03-22 2022-01-13 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition
EP3714889A1 (en) * 2019-03-29 2020-09-30 F. Hoffmann-La Roche AG Baloxavir for the prevention of transmission of influenza virus
WO2021038480A1 (en) * 2019-08-27 2021-03-04 Janssen Pharmaceuticals, Inc. Combinations for treating influenza virus
WO2021084725A1 (ja) * 2019-10-31 2021-05-06 フジデノロ株式会社 検出装置、磁気組成物、及び、管理システム
CN111647005A (zh) * 2020-06-15 2020-09-11 安徽皓元药业有限公司 巴洛沙韦新晶型及其制备方法
CN112730682B (zh) * 2020-12-25 2022-06-17 苏州海科医药技术有限公司 一种抗病毒药物临床研究血浆样本中奥司他韦及代谢物奥司他韦酸浓度的生物分析方法
CN114306261A (zh) * 2021-12-15 2022-04-12 澳美制药(苏州)有限公司 巴洛沙韦酯片及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19831869A1 (de) * 1998-07-16 2000-01-20 Merck Patent Gmbh Farbgebung mit Perlglanzpigmenten im Lebensmittel- und Pharmabereich
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
EP1460062A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical NITROGEN-CONTAINING CYCLIC KETONE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
SE0203778D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
ES2375643T3 (es) 2005-10-31 2012-03-02 Kowa Company, Ltd. Preparación farmacéutica que presenta excelente fotoestabilidad.
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JP2008201712A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd フィルムコーティング製剤
WO2008114859A1 (ja) * 2007-03-22 2008-09-25 Astellas Pharma Inc. ピラゾール誘導体を含有する医薬組成物
EP2320909B8 (en) * 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
JP5644167B2 (ja) 2009-04-21 2014-12-24 大正製薬株式会社 溶出改善されたケトチフェン又はその塩を含有する固形製剤
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
TWI541030B (zh) * 2010-07-06 2016-07-11 健生藥品公司 用於糖尿病協同治療之調配物
JP4803686B2 (ja) * 2010-08-31 2011-10-26 協和発酵キリン株式会社 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠
WO2012144592A1 (ja) 2011-04-22 2012-10-26 アステラス製薬株式会社 固形医薬組成物
CN103648485A (zh) * 2011-05-20 2014-03-19 阿斯利康(英国)有限公司 罗苏伐他汀钙的药物组合物
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
JP2015054822A (ja) * 2013-09-10 2015-03-23 ニプロ株式会社 クロピドグレル含有錠剤およびその製造方法
JP2015054851A (ja) 2013-09-13 2015-03-23 大鵬薬品工業株式会社 被覆経口固形製剤
BR112016010716A8 (pt) * 2013-11-13 2020-04-22 Novartis Ag dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
US10287354B2 (en) * 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
CA2984130C (en) * 2015-04-28 2021-07-20 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
WO2016204291A1 (ja) * 2015-06-18 2016-12-22 共同印刷株式会社 ブリスターパック用積層体、及びそれを用いたブリスターパック
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug

Also Published As

Publication number Publication date
AU2018369241B2 (en) 2023-01-05
TWI795462B (zh) 2023-03-11
JP7251891B2 (ja) 2023-04-04
CN111615390A (zh) 2020-09-01
IL274625B (en) 2022-08-01
BR112020009634B1 (pt) 2022-08-30
US20200375998A1 (en) 2020-12-03
JP6660644B2 (ja) 2020-03-11
KR102562514B1 (ko) 2023-08-03
JPWO2019098259A1 (ja) 2019-12-12
AU2018369241A1 (en) 2020-06-18
TW201922259A (zh) 2019-06-16
IL274625A (en) 2020-06-30
WO2019098259A1 (ja) 2019-05-23
KR20200089290A (ko) 2020-07-24
CA3082522A1 (en) 2019-05-23
EP3711767A4 (en) 2021-12-01
JP2020079283A (ja) 2020-05-28
EP3711767A1 (en) 2020-09-23
AR113890A1 (es) 2020-06-24
BR112020009634A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
MX2020004680A (es) Preparado farmaceutico con excelentes propiedades de estabilidad a la luz y disolucion.
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2018002060A2 (es) Compuestos farmacéuticos
DOP2018000241A (es) Derivados aromáticos de sulfonamida
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
CU20170154A7 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR095034A1 (es) El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20180308A (es) Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
AR106025A1 (es) Formas cristalinas de ácido siálico o una sal o solvato de este
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112021024948A2 (pt) Moduladores de próxima geração de estimulador de genes de interferon (sting)
AR093188A1 (es) Sal y uso medico